Diligence memo · auto-generated · as of July 2, 2026
HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
HOOKIPA Pharma Inc. operates in Pharmaceuticals, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
HOOKIPA Pharma Inc. has raised $37M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $37M on 2019-02-15.
Most recent recorded round closed around 2019-02-15.
Valuation (modeled)modeled
Provath models HOOKIPA Pharma Inc. at approximately $1.3B (range $79M–$4.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.57× the median modeled value of Series B Pharmaceuticals companies in 2019–2021 (61 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 7.4 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 77% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Evolus, Inc., ESSA Pharma Inc., Pieris Pharmaceuticals, Inc., Amylyx Pharmaceuticals, Inc., PassPort Technologies, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.